Document Detail


The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.
MedLine Citation:
PMID:  22646065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The cerebrospinal fluid (CSF) biomarkers β-amyloid(1-42) (Aβ(1-42)), total tau protein (T-tau), and tau phosphorylated at threonine 181 (P-tau(181P)) are gradually finding their way into routine clinical practice as an affirmative diagnostic tool for Alzheimer's disease (AD). These biomarkers have also been implemented in the revised diagnostic criteria for AD. The combination of the CSF biomarkers Aβ(1-42), T-tau, and P-tau(181P) leads to high (around 80%) levels of sensitivity, specificity, and diagnostic accuracy for discrimination between AD and controls (including psychiatric disorders like depression) and can be applied for diagnosing AD in the predementia phases of the disease (mild cognitive impairment). The added value of CSF biomarkers could lie within those cases in which the clinical diagnostic work-up is not able to discriminate between AD and non-AD dementias. However, their discriminatory power for the differential diagnosis of dementia is suboptimal. Other CSF biomarkers, especially those that are reflective of the pathology of non-AD dementia etiologies, could improve the accuracy of differential dementia diagnosis. CSF biomarkers will be of help to establish a correct and early AD diagnosis, even in the preclinical stages of the disease, which will be of importance once disease-modifying drugs for AD become available. Variation in biomarker measurements still jeopardize the introduction of CSF biomarkers into routine clinical practice and clinical trials, but several national and international standardization initiatives are ongoing.
Authors:
Sebastiaan Engelborghs; Nathalie Le Bastard
Related Documents :
7341585 - Indications of unilateral bovine nephrectomy: a report of four cases.
9097245 - Duplex doppler measurements of renal blood flow in a dog with addison's disease.
16893405 - Intravenous iron therapy in end-stage renal disease.
7865385 - Clinical aspects of systemic and localized scleroderma.
1203865 - Hodgkin's disease in the bone marrow.
18598105 - The future of rip2/rick/cardiak as a biomarker of the inflammatory response to infection.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-31     Completed Date:  2012-11-19     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  135-41     Citation Subset:  IM    
Affiliation:
Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. sebastiaan.engelborghs@ua.ac.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / cerebrospinal fluid*,  diagnosis*
Amyloid beta-Peptides / cerebrospinal fluid*
Biological Markers
Cognition Disorders / cerebrospinal fluid,  diagnosis
Diagnosis, Differential
Early Diagnosis
Humans
Peptide Fragments / cerebrospinal fluid*
Phosphorylation
Sensitivity and Specificity
tau Proteins / cerebrospinal fluid*
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/Peptide Fragments; 0/amyloid beta-protein (1-42); 0/tau Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of patient acceptance of sodium phosphate versus polyethylene glycol plus sodium picosulf...
Next Document:  Glycopyrrolate Oral Solution: For Chronic, Severe Drooling in Pediatric Patients with Neurologic Con...